Oral Cannabigerol (CBG): What a New Human Safety Study Actually Found
Cannabigerol CBG safety study: a controlled human trial in 12 healthy adults found oral CBG well tolerated up to 200 mg, with no drug-related adverse events, minimal psychoactive effects, and normal liver function tests throughout. It keeps the evidence…
Cannabigerol induces endoplasmic reticulum stress-mediated apoptosis and ferroptosis via the IRE1α-XBP1 axis in human pancreatic cancer cells.
Cannabigerol (CBG), a non-psychoactive phytocannabinoid derived from Cannabis sativa, has attracted increasing attention owing to its antibiotic, anti-inflam...
Exploring the neuroprotective effects of phytocannabinoids on oxygen-glucose deprived neurons in an in vitro model of stroke.
Recent laboratory research on cannabinoids for stroke neuroprotection showed modest benefits from seven phytocannabinoids in protecting brain cells. While promising, these early findings require extensive additional research before clinical applications.
Cannabidiol and Cannabigerol Ameliorate Steatotic Liver Disease
Cannabidiol and cannabigerol fatty liver effects show promise in improving metabolic liver disease. These cannabinoids work through phosphocreatine buffering and lysosomal restoration. This study highlights their potential therapeutic roles in steatotic…
Exploring Neuroprotective Effects of Phytocannabinoids in Stroke Models
Phytocannabinoids neuroprotection stroke research explores their potential to reduce neuronal damage in stroke. This study used oxygen-glucose deprived neurons to model stroke conditions. Findings highlight modest neuroprotective effects of certain…